Regulatory approval

Published by the Health Service Executive. Approved

The treatment of adults with mismatch repair deficient (dMMR) / microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy.

This is written in the approval document.

Reimbursement

Incomplete Reimbursement

dostarlimab - ODMS; carboplatin and paclitaxel - N/A

Citation

Dostarlimab, PACLitaxel and CARBOplatin Therapy, 2026, version number 1, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/8284/929_Dostarlimab_-_PACLi_CARBO_Regimen.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	dMMR	Endometrial Carcinoma	Carboplatin, Dostarlimab, Paclitaxel
HSE (1)	MSI-H	Endometrial Carcinoma	Carboplatin, Dostarlimab, Paclitaxel

Contributions

Date	Contributor	Description
2026-08-02	Van Allen lab	Initial curation of into moalmanac-db
2026-04-01	Health Service Executive	Indication approved for reimbursement.